Development of the Vitamin B12 Analog cobinamide as a Hydrogen Sulfide Antidote
开发维生素 B12 类似物椰酰胺作为硫化氢解毒剂
基本信息
- 批准号:9762596
- 负责人:
- 金额:$ 82.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-01 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:AgreementAnimal ModelAnimalsAntidotesBindingCarbon MonoxideCardiovascular systemCellsCobaltComaCyanidesDataDevelopmentDoseDrug KineticsExposure toFamily suidaeFormulationGasesGrantHumanHydrogen SulfideHydroxocobalaminImpairmentIndustrial AccidentsIndustrializationIndustryInfusion proceduresInhalationInjuryInternationalIntramuscularIntramuscular InjectionsIntravenousIntravenous infusion proceduresLesionLungModelingMonitorMusNebulizerNeurologicNeurologic DeficitNeurologic DysfunctionsNitritesNon-Rodent ModelOryctolagus cuniculusPathway interactionsPersonsPetroleumPharmaceutical PreparationsPhase I Clinical TrialsPlasmaPoisoningPropertyRattusRecurrenceResearch PersonnelRouteServicesSodiumSodium NitriteSuicideSulfidesSurvivorsSymptomsSyringesTerrorismTestingTherapeuticTimeToxic effectToxicologyUltrasonicsUnconscious StateVitamin B 12WaterWorkanaloganimal ruleaqueouscobinamidedrug inhalationexperimental studyexposed human populationfirst responderflyintravenous injectionmass casualtymeetingsneurobehavioralnovel therapeuticsparenteral administrationpreferencepreventprophylacticpublic health relevancesuicidalweapons of mass destruction
项目摘要
DESCRIPTION (provided by applicant): Hydrogen sulfide is an extremely toxic gas for which no treatment is available. Workers in a variety of industries are exposed to hydrogen sulfide most notably the petroleum industry, where one-third of workers are exposed to sufficient gas to have symptoms, with 8% having suffered loss of consciousness. Moreover, inhalation of hydrogen sulfide gas is a common mode of suicide and the gas could be used by terrorists as a weapon of mass destruction. Survivors of sulfide exposure can develop long-term neurological abnormalities, with even one brief exposure leading to neurological deficits. We have found that the vitamin B12 analog cobinamide rescues mice, rabbits, and pigs from lethal doses of sulfide, and reduces the neurobehavioral impairment and neuropathological lesions from sulfide-induced coma in rats. Nitrocobinamide, i.e., cobinamide with two nitrite groups bound to the cobalt atom, is well absorbed after intramuscular injection, which is generally the preferred administration route for treating a large number of victims as in a major industrial accident or a terrorist attack. Nitrocobinamide is both very stable and soluble in aqueous solutions; these properties, along with its high degree of potency, would allow it to be packaged in a small pre-filled syringe and be administered quickly via an autoinjector. We estimate that less than 3 ml of a 225 mM nitrocobinamide solution would rescue a human from a lethal sulfide exposure. This volume could also be administered by inhalation using newly-developed, high-flow ultrasonic nebulizers. Inhalational delivery could be used both in a therapeutic and prophylactic mode, with the latter being particularly applicable to first responders, who frequently succumb to the sulfide
gas. In the proposed studies, we will define the nitrocobinamide dose required to rescue rabbits, pigs, and mice from lethal sulfide exposures. The rabbits and pigs will receive an infusion of intravenous sodium hydrogen sulfide, and, in separate experiments, the mice and rabbits will be exposed to hydrogen sulfide gas. In addition to simulating human exposure, the inhalation experiments will allow us to determine if nebulized nitrocobinamide is more effective than injected nitrocobinamide at protecting the lungs from inhaled hydrogen sulfide gas. We will also define the nitrocobinamide dose to prevent the neurological sequelae of sulfide-induced coma, and how long after the onset of coma nitrocobinamide can be administered and still prevent neurological dysfunction. Once we have determined the nitrocobinamide dose for both intramuscular injection and inhalational delivery, we will conduct the pharmacokinetic and toxicology studies necessary for an FDA Investigators New Drug (IND) application. We will then have a pre-IND meeting with the FDA and submit an IND application. By the end of the grant period, we expect to be ready to start Phase I Clinical Trials, and to have developed a drug for treating sulfide poisoning-a frequently lethal condition for which no treatment currently exists.
描述(由申请人提供):硫化氢是一种剧毒气体,无法进行处理。许多行业的工人都暴露在硫化氢中,尤其是石油行业,三分之一的工人暴露在足够的气体中,出现症状,其中8%的工人失去意识。此外,吸入硫化氢气体是一种常见的自杀方式,这种气体可能被恐怖分子用作大规模杀伤性武器。硫化物暴露的幸存者可以发展长期的神经系统异常,即使是一个短暂的暴露导致神经功能缺损。我们已经发现,维生素B12类似物cobinamide拯救小鼠,兔子和猪从致命剂量的硫化物,并减少神经行为障碍和神经病理学病变的硫化物诱导的昏迷大鼠。硝基烟酰胺,即,具有与钴原子结合的两个亚硝酸根基团的可宾酰胺在肌内注射后被很好地吸收,肌内注射通常是治疗大量受害者(如在重大工业事故或恐怖袭击中)的优选给药途径。硝代烟酰胺在水溶液中非常稳定且可溶;这些性质,沿着其高度效力,将允许其包装在小型预充式注射器中并通过自动注射器快速给药。我们估计,少于3毫升的225 mM的硝基烟酰胺溶液将拯救一个人从致命的硫化物暴露。该体积也可以使用新开发的高流量超声雾化器通过吸入给药。吸入给药既可用于治疗,也可用于预防,后者特别适用于第一反应者,他们经常死于硫化物
气体在拟议的研究中,我们将确定从致命的硫化物暴露中拯救兔子、猪和小鼠所需的硝代烟酰胺剂量。兔子和猪将接受静脉注射硫化氢钠,在单独的实验中,小鼠和兔子将暴露于硫化氢气体。除了模拟人体暴露外,吸入实验还将使我们能够确定雾化的硝基烟酰胺是否比注射的硝基烟酰胺更有效地保护肺部免受吸入硫化氢气体的影响。我们还将确定预防硫化物诱导昏迷的神经系统后遗症的硝氨酰胺剂量,以及在昏迷发作后多久可以给予硝氨酰胺并仍然预防神经功能障碍。一旦我们确定了肌内注射和吸入给药的硝氨酰胺剂量,我们将进行FDA研究者新药(IND)申请所需的药代动力学和毒理学研究。然后,我们将与FDA举行IND前会议,并提交IND申请。到资助期结束时,我们预计将准备好开始第一阶段临床试验,并开发出一种治疗硫化物中毒的药物,硫化物中毒是一种目前没有治疗方法的常见致命疾病。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GERRY R BOSS其他文献
GERRY R BOSS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GERRY R BOSS', 18)}}的其他基金
Development of the Vitamin B12 Analog cobinamide as a Hydrogen Sulfide Antidote
开发维生素 B12 类似物椰酰胺作为硫化氢解毒剂
- 批准号:
9324373 - 财政年份:2015
- 资助金额:
$ 82.62万 - 项目类别:
Development of the Vitamin B12 Analog cobinamide as a Hydrogen Sulfide Antidote
开发维生素 B12 类似物椰酰胺作为硫化氢解毒剂
- 批准号:
9128073 - 财政年份:2015
- 资助金额:
$ 82.62万 - 项目类别:
Blood Donor Drives & High School Students to Educate People About Organ Donation
献血活动
- 批准号:
8503816 - 财政年份:2012
- 资助金额:
$ 82.62万 - 项目类别:
Blood Donor Drives & High School Students to Educate People About Organ Donation
献血活动
- 批准号:
8720768 - 财政年份:2012
- 资助金额:
$ 82.62万 - 项目类别:
Blood Donor Drives & High School Students to Educate People About Organ Donation
献血活动
- 批准号:
9107866 - 财政年份:2012
- 资助金额:
$ 82.62万 - 项目类别:
Validating promising drug candidates in mammalian models of CN poisoning
在哺乳动物 CN 中毒模型中验证有前途的候选药物
- 批准号:
8411687 - 财政年份:2012
- 资助金额:
$ 82.62万 - 项目类别:
Blood Donor Drives & High School Students to Educate People About Organ Donation
献血活动
- 批准号:
8549238 - 财政年份:2012
- 资助金额:
$ 82.62万 - 项目类别:
Testing the Vitamin B12 Analog Cobinamide Against Selected Chemical Threats
测试维生素 B12 类似物椰酰胺对选定化学威胁的影响
- 批准号:
8214958 - 财政年份:2011
- 资助金额:
$ 82.62万 - 项目类别:
Testing the Vitamin B12 Analog Cobinamide Against Selected Chemical Threats
测试维生素 B12 类似物椰酰胺对选定化学威胁的影响
- 批准号:
8337307 - 财政年份:2011
- 资助金额:
$ 82.62万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 82.62万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 82.62万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 82.62万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 82.62万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 82.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 82.62万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 82.62万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 82.62万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 82.62万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 82.62万 - 项目类别:
Grant-in-Aid for Early-Career Scientists